Interview: AC Immune CEO Reflects On Alzheimer's R&D Post-CREAD
Executive Summary
The recent failure of the CREAD studies to show a therapeutic effect for crenezumab in Alzheimer’s disease stunned developers. However, an ongoing clinical study of the MAb, and a series of other innovations being explored at Switzerland’s AC Immune, might still provide answers to this intractable condition.